Multiple analysts reiterated their 'buy' ratings for Cardinal Health, with some adjusting price targets upwards. This indicates continued positive sentiment from the analyst community, which could provide some upward momentum for the stock.
On November 6, 2026, several prominent analysts updated their coverage on Cardinal Health. Barclays and Evercore maintained their 'buy' ratings with price targets of $275 and $270, respectively. Mizuho Securities raised its price target from $280 to $290, and Baird increased its target from $248 to $305, all while maintaining 'buy' ratings. This collective positive sentiment from multiple analysts, particularly the upward revisions in price targets, suggests a continued bullish outlook for Cardinal Health. For traders, this could signal a short-term opportunity for upward price movement as the market digests these positive analyst views, reinforcing investor confidence in the company's future performance.